Share on LinkedInShare on LinkedIn

ARTICLE · 14 NOVEMBER 2025

Competition Monthly – November 2025 Edition

Phoenix Legal
Phoenix Legal
Contributor
Phoenix Legal

Phoenix Legal

Phoenix Legal is a leading full-service Indian law firm, founded in 2008, providing comprehensive...

View firm profile
Explore more from Phoenix Legal

The National Company Law Appellate Tribunal (NCLAT), by its order dated 30 October 2025, dismissed an appeal challenging an order of the Competition Commission of India (CCI) closing a case...

IndiaAntitrust/Competition Law

NCLAT RULES THAT CCI HAS NO POWER TO INVESTIGATE PATENT DISPUTES

The National Company Law Appellate Tribunal (NCLAT), by its order dated 30 October 2025, dismissed an appeal challenging an order of the Competition Commission of India (CCI) closing a case against Vifor International (AG) under Section 26(2) of the Competition Act, 2002 (Act).

The appellant, CEO of a hospital providing dialysis services under a government programme, had alleged that Vifor International, the Swiss developer and patent holder of the drug Ferric Carboxymaltose (FCM) used in treating iron deficiency anaemia, is engaged in anticompetitive practices by limiting access and keeping prices high. It was alleged that Vifor's exclusive licensing arrangements with Emcure Pharmaceuticals Ltd. and Lupin Ltd. violated Sections 3 and 4 of the Act.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from